(SeaPRwire) –   – Showcased core product lines spanning aesthetic, wound care, bone and spine, and surgical sectors
– Secured supply agreements totaling KRW 5.3 billion with partners from Singapore, Malaysia, Pakistan, Taiwan, and the Philippines

SEOUL, South Korea, April 7, 2026 — CGBIO (CEO Hyunseung Yu), a biotechnology company specializing in regenerative medicine, announced on April 6 that it participated in the 41st Korea International Medical & Hospital Equipment Show (KIMES 2026), recently held at COEX in Seoul, where it showcased products across aesthetic, wound care, bone and spine, and surgical fields, and signed overseas supply contracts worth a total of KRW 5.3 billion with partners from five countries.

KIMES is a premier medical device and hospital equipment exhibition that gathers healthcare professionals, industry stakeholders, and domestic and international buyers to explore cutting-edge medical technologies and market trends. At this year’s event, CGBIO didn’t just showcase individual products, but also highlighted its integrated solution strengths by linking together its core product lineup.

Standout products at the exhibition included FACETEM (aesthetic), Curasys ME (wound care), NOVOSIS (bone substitute), and CG GEL (endoscopic hemostatic agent).

FACETEM is a collagen stimulator that outperforms traditional fillers by triggering the body’s natural collagen production, catering to the global aesthetic market’s increasing focus on natural volume enhancement and skin regeneration. Curasys ME is a next-generation negative pressure wound therapy (NPWT) device engineered with the convenience of medical practitioners and patients in mind, delivering a more streamlined wound care environment. NOVOSIS, renowned for its exceptional osteoinductive capabilities, showcases CGBIO’s technical edge in the bone and spine sector. CG GEL, an endoscopic hemostatic agent, proved its suitability for surgical and clinical procedures by effectively stopping bleeding during endoscopic treatments.

In addition, CGBIO displayed a broad portfolio of products across multiple categories, including AILEENE, GISELLELIGNE, LUXX, DOOTH, Curasys2, CuraVAC Double Channel, BELUNA, NOVOMAX, Verteon, EXCENDER, CUVIS-Spine, Solendos Endo Tower, Realist Bone Model, ARISTENT, and NOVONIX.

Throughout the exhibition, CGBIO fortified its groundwork for global market growth by putting forward customized strategies tailored to each country’s unique healthcare landscape and partner requirements. Via in-person consultations, the company deepened its connections with international buyers by outlining the clinical value and practical uses of each product category.

Contract signing events with overseas partners also took place over the course of the exhibition. CGBIO inked exclusive supply deals with Neuva Era for FACETEM in Singapore and Malaysia, and with MediNova Healthcare for the exclusive distribution of FACETEM in Pakistan. Furthermore, the company entered into a supply agreement with HCT Regenerative Co., Ltd. for CGDerm One-Step in Taiwan, and with Variance Trading Corporation for wound care product lines including Curasys, CuraVAC, EasyFoam, and Easydew MD Cream in the Philippines.

Hyunseung Yu, CEO of CGBIO, shared, “KIMES 2026 gave CGBIO a chance to showcase its strengths as a comprehensive medical device solution provider, moving past a single-product focus.” He added, “We will keep expanding our overseas business footprint through targeted product pitches and partnerships customized to the needs of each market and collaborator.”

Photo: http://rssdatabase.tickerwit.com/images/156/114156_2.jpg
Logo: http://rssdatabase.tickerwit.com/images/156/114156_3.jpg